Four-miRNA Signature to Identify Asbestos-Related Lung Malignancies.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
01 2019
Historique:
received: 24 04 2018
revised: 29 06 2018
accepted: 17 09 2018
pubmed: 28 9 2018
medline: 12 2 2020
entrez: 28 9 2018
Statut: ppublish

Résumé

Altered miRNA expression is an early event upon exposure to occupational/environmental carcinogens; thus, identification of a novel asbestos-related profile of miRNAs able to distinguish asbestos-induced cancer from cancer with different etiology can be useful for diagnosis. We therefore performed a study to identify miRNAs associated with asbestos-induced malignancies. Four groups of patients were included in the study, including patients with asbestos-related (NSCLC Four serum miRNAs, that is miR-126, miR-205, miR-222, and miR-520g, were found to be implicated in asbestos-related malignant diseases. Notably, increased expression of miR-126 and miR-222 were found in asbestos-exposed subjects, and both miRNAs are involved in major pathways linked to cancer development. Epigenetic changes and cancer-stroma cross-talk could induce repression of miR-126 to facilitate tumor formation, angiogenesis, and invasion. This study indicates that miRNAs are potentially involved in asbestos-related malignancies, and their expression outlines mechanism(s) whereby miRNAs may be involved in an asbestos-induced pathogenesis. The discovery of a miRNA panel for asbestos-related malignancies would impact on occupational compensation and may be utilized for screening asbestos-exposed populations.

Sections du résumé

BACKGROUND
Altered miRNA expression is an early event upon exposure to occupational/environmental carcinogens; thus, identification of a novel asbestos-related profile of miRNAs able to distinguish asbestos-induced cancer from cancer with different etiology can be useful for diagnosis. We therefore performed a study to identify miRNAs associated with asbestos-induced malignancies.
METHODS
Four groups of patients were included in the study, including patients with asbestos-related (NSCLC
RESULTS
Four serum miRNAs, that is miR-126, miR-205, miR-222, and miR-520g, were found to be implicated in asbestos-related malignant diseases. Notably, increased expression of miR-126 and miR-222 were found in asbestos-exposed subjects, and both miRNAs are involved in major pathways linked to cancer development. Epigenetic changes and cancer-stroma cross-talk could induce repression of miR-126 to facilitate tumor formation, angiogenesis, and invasion.
CONCLUSIONS
This study indicates that miRNAs are potentially involved in asbestos-related malignancies, and their expression outlines mechanism(s) whereby miRNAs may be involved in an asbestos-induced pathogenesis.
IMPACT
The discovery of a miRNA panel for asbestos-related malignancies would impact on occupational compensation and may be utilized for screening asbestos-exposed populations.

Identifiants

pubmed: 30257964
pii: 1055-9965.EPI-18-0453
doi: 10.1158/1055-9965.EPI-18-0453
doi:

Substances chimiques

Biomarkers, Tumor 0
Carcinogens 0
MIRN126 microRNA, human 0
MIRN205 microRNA, human 0
MIRN222 microRNA, human 0
MicroRNAs 0
Asbestos 1332-21-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

119-126

Informations de copyright

©2018 American Association for Cancer Research.

Auteurs

Lory Santarelli (L)

Department of Clinical and Molecular Sciences, Section of Occupational Medicine, Polytechnic University of Marche, Ancona, Italy. m.tomasetti@staff.univpm.it l.santarelli@staff.univpm.it.

Simona Gaetani (S)

Department of Clinical and Molecular Sciences, Section of Occupational Medicine, Polytechnic University of Marche, Ancona, Italy.

Federica Monaco (F)

Department of Clinical and Molecular Sciences, Section of Occupational Medicine, Polytechnic University of Marche, Ancona, Italy.

Massimo Bracci (M)

Department of Clinical and Molecular Sciences, Section of Occupational Medicine, Polytechnic University of Marche, Ancona, Italy.

Matteo Valentino (M)

Department of Clinical and Molecular Sciences, Section of Occupational Medicine, Polytechnic University of Marche, Ancona, Italy.

Monica Amati (M)

Department of Clinical and Molecular Sciences, Section of Occupational Medicine, Polytechnic University of Marche, Ancona, Italy.

Corrado Rubini (C)

Department of Biomedical Sciences and Public Health, Section of Anatomical Pathology, Polytechnic University of Marche, Ancona, Italy.

Armando Sabbatini (A)

Division of Thoracic Surgery, United Hospitals, Ancona, Italy.

Ernesto Pasquini (E)

ENT Metropolitan Unit, Bellaria Hospital, AUSL Bologna, Bologna, Italy.

Nunzia Zanotta (N)

Institute for Maternal and Child Health-IRCCS "Burlo Garofolo," Trieste, Italy.

Manola Comar (M)

Institute for Maternal and Child Health-IRCCS "Burlo Garofolo," Trieste, Italy.
Department of Medical Sciences, University of Trieste, Trieste, Italy.

Jiri Neuzil (J)

Mitochondria, Apoptosis and Cancer Research Group, School of Medical Science, Griffith University, Southport, Australia.
Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.

Marco Tomasetti (M)

Department of Clinical and Molecular Sciences, Section of Occupational Medicine, Polytechnic University of Marche, Ancona, Italy. m.tomasetti@staff.univpm.it l.santarelli@staff.univpm.it.
International Society of Doctors for the Environment (ISDE), Arezzo, Italy.

Massimo Bovenzi (M)

Department of Medical Sciences, University of Trieste, Trieste, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH